Rohto Pharmaceutical Co.,Ltd.

BMV:4527 N Stock Report

Market Cap: Mex$84.0b

Rohto PharmaceuticalLtd Past Earnings Performance

Past criteria checks 4/6

Rohto PharmaceuticalLtd has been growing earnings at an average annual rate of 23.1%, while the Personal Products industry saw earnings growing at 7.6% annually. Revenues have been growing at an average rate of 8.5% per year. Rohto PharmaceuticalLtd's return on equity is 12.7%, and it has net margins of 11.4%.

Key information

23.1%

Earnings growth rate

23.1%

EPS growth rate

Personal Products Industry Growth12.9%
Revenue growth rate8.5%
Return on equity12.7%
Net Margin11.4%
Next Earnings Update07 Aug 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Rohto PharmaceuticalLtd makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

BMV:4527 N Revenue, expenses and earnings (JPY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Mar 24270,84030,936101,30613,390
31 Dec 23263,56430,89799,52711,065
30 Sep 23256,22029,77997,05411,065
30 Jun 23247,58028,47393,41111,065
31 Mar 23238,66426,37790,47911,065
31 Dec 22231,88725,72289,0988,740
30 Sep 22218,94023,45484,2628,740
30 Jun 22209,58623,28180,3448,740
31 Mar 22199,64621,01877,4608,740
31 Dec 21195,69822,59376,6367,903
30 Sep 21189,30221,32176,2727,903
30 Jun 21184,96119,53775,0197,903
31 Mar 21181,28716,74375,1477,903
31 Dec 20179,81913,93177,9977,050
30 Sep 20180,90314,28378,0527,050
30 Jun 20185,05815,13080,8407,050
31 Mar 20188,32715,41082,7337,050
31 Dec 19187,00611,49082,3216,831
30 Sep 19186,7519,78782,5486,831
30 Jun 19184,8548,57682,1926,831
31 Mar 19183,5829,79980,6026,831
31 Dec 18182,32810,05880,1896,553
30 Sep 18180,50310,95978,7526,553
30 Jun 18176,54310,45476,1776,553
31 Mar 18171,7429,28974,1066,553
31 Dec 17167,28611,69972,4406,123
30 Sep 17161,79911,46769,9296,123
30 Jun 17157,55710,91368,7836,123
31 Mar 17154,59910,01168,4146,123
31 Dec 16158,1159,70569,5385,811
30 Sep 16160,9738,41673,0025,811
30 Jun 16164,4679,14374,1405,811
31 Mar 16167,0169,09876,2415,811
31 Dec 15164,63910,59175,7465,585
30 Sep 15161,8529,92674,7095,585
30 Jun 15157,1679,31172,3175,585
31 Mar 15151,7748,63170,5515,585
31 Dec 14148,1676,60869,4234,547
30 Sep 14146,4958,00266,8554,547
30 Jun 14143,9007,67665,3964,547
31 Mar 14143,8228,94763,7174,547
31 Dec 13139,6139,18361,3434,062
30 Sep 13134,9799,16258,8884,062

Quality Earnings: 4527 N has high quality earnings.

Growing Profit Margin: 4527 N's current net profit margins (11.4%) are higher than last year (11.1%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: 4527 N's earnings have grown significantly by 23.1% per year over the past 5 years.

Accelerating Growth: 4527 N's earnings growth over the past year (17.3%) is below its 5-year average (23.1% per year).

Earnings vs Industry: 4527 N earnings growth over the past year (17.3%) exceeded the Personal Products industry 13.9%.

Return on Equity

High ROE: 4527 N's Return on Equity (12.7%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/07/10 03:43
End of Day Share Price 2024/04/12 00:00
Earnings2024/03/31
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Rohto Pharmaceutical Co.,Ltd. is covered by 17 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Mitsuko MiyasakoBarclays
Hidemaru YamaguchiCitigroup Global Markets Japan Inc.
Hidemaru YamaguchiCitigroup Inc